BioAffinity Technologies, a company focused on noninvasive cancer diagnostics, has announced the pricing of a public offering expected to generate approximately $4.8 million. The raise will be structured through a combination of common stock shares and pre-funded warrants, giving investors added flexibility.
Supporting Early Cancer Detection
The proceeds will primarily fund research and development, regulatory activities, and commercialization efforts across BioAffinity’s pipeline. A portion will also go toward general corporate purposes, including working capital. The company’s mission centers on improving early cancer detection with patient-friendly, noninvasive tools — a fast-growing area of demand within healthcare.
Focus on CyPath® Lung Test
At the center of BioAffinity’s development efforts is its CyPath® Lung test, which identifies early-stage lung cancer through sputum analysis. By enabling physicians to diagnose cancers at earlier and more manageable stages, the test has the potential to significantly improve patient outcomes.
Investor Backing Amid Selective Market
Although relatively modest in scale, the $4.8 million raise comes at a pivotal moment for BioAffinity. The offering signals continued investor confidence in precision diagnostics, even in a more selective biotech funding environment. For the company, the new capital provides crucial runway and momentum as it seeks broader clinical adoption and market penetration.
Positioning in Precision Diagnostics
The financing round underscores BioAffinity’s role within a competitive but vital healthcare segment. As health systems prioritize early detection and less invasive approaches, innovations like CyPath® Lung could play a transformative role in reshaping diagnostic pathways for cancer care.
